In a report released today, Michael Petusky from Barrington maintained a Buy rating on Orthofix, with a price target of $17.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Petusky has given his Buy rating due to a combination of factors, including Orthofix’s strong financial performance in the second quarter. The company’s revenue of $203.1 million surpassed both the firm’s and the consensus estimates, driven by robust sales in bone growth therapies and global orthopedics. Additionally, Orthofix’s adjusted earnings per share and EBITDA significantly exceeded expectations, reflecting effective expense management and operational efficiency.
Orthofix’s balance sheet remains solid with $68.7 million in cash and restricted cash, alongside a manageable debt level. The company also reaffirmed its financial guidance for 2025, projecting continued revenue growth and positive free cash flow. These positive financial indicators, combined with an increased price target of $17, support Petusky’s optimistic outlook and Buy rating for Orthofix’s stock.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $22.00 price target.